Principal Physicist (Molecular Radiotherapy)
NHS AfC: Band 8b
Main area Nuclear Medicine Grade NHS AfC: Band 8b Contract Fixed term: 12 months (Maternity cover) Hours Full time – 37.5 hours per week Job ref 309-UCLH-7989-A
Site University College Hospital Town London Salary £75,328 – £86,114 per annum inclusive of HCAS Salary period Yearly Closing 05/07/2026 23:59
The use of AI is monitored and if applicants have used it, then they are required to declare this in their supporting statement.
Artificial intelligence (AI) is a set of technology that can perform various tasks that typically required human intelligence. Your application is your opportunity to demonstrate to us how you meet the requirements of the role.
We recognise that AI tools can support accessibility, equity and confidence for applicants. However, it’s important that examples and responses genuinely reflect your own experience and abilities, as these will be explored further during the selection process. AI must not be used to provide misleading or false information during any stage of the application journey.
University College London Hospitals NHS Foundation Trust is committed to fair and transparent recruitment and requires applicants to provide accurate information, as misleading details may affect their application or employment and may be verified in line with the Fraud Act 2006. For further information please visit https://royalfree.pagetiger.com/cuuomnr/1 .
Job overview
This 12‑month fixed‑term (maternity cover) role is for a Principal Clinical Scientist in a joint clinical‑academic department within a large London teaching hospital. While covering the full scope of nuclear medicine physics, the primary focus is leading the physics aspects of the Molecular Radiotherapy (MRT) service. The role is relatively new and has been driven by the transfer of the in‑patient MRT service from radiotherapy physics to nuclear medicine physics. This service includes inpatient thyroid cancer treatments and a national referral centre for somatostatin therapies (I‑131 mIBG and Lu‑177 Dotatate). There is also a significant paediatric MRT workload. In addition, the department runs a busy out‑patient MRT service, including NHS‑funded benign thyroid and radium‑223 treatments, a large private Lu‑177 PSMA service, and a growing research programme using Lu-177, Ac-225 and other radionuclide labelled ligands. Support
#J-18808-Ljbffr…